ArticleScientific reports2026
Prevalence of sarcopenia and population attributable fraction of related factors in Iranian older adults from the IMOS‑2021 study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recognizing the growing impact of sarcopenia among older adults in Iran, this study aimed to estimate its prevalence and quantify the population-attributable fraction (PAF) of potential risk factors using data from the Iranian Multicenter Osteoporosis Study (IMOS-2021). A total of 705 participants aged ≥ 60 years completed the IMOS examinations. Sarcopenia was defined as the coexistence of low muscle mass and low muscle strength, and severe sarcopenia as low muscle mass, low muscle strength, and low physical performance. Complex survey analysis was used to calculate the weighted prevalence, and multivariable Poisson regression models were applied to identify associated risk factors and subsequently, their PAFs. The mean age of participants was 67.2 years, and 50.4% were women. The weighted prevalence of sarcopenia was 13.8% (11.1-17.0%), increasing significantly with age (P for trend < 0.001). A body mass index (BMI) < 25 showed a strong association [APR = 5.80 (2.40-13.97)] and the highest PAF (51.0%) for sarcopenia, followed by high fat mass [APR = 2.31 (1.47-3.64); PAF = 42.39%]. Other possible contributing factors were low physical activity (PAF = 28.71%), and small calf circumference (PAF = 16.55%). Sarcopenia is relatively prevalent among Iranian older adults. Low BMI, high adiposity, and low physical activity are key modifiable targets, highlighting the need for prompt nationwide interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.